Regeneron Pharmaceuticals, Inc. (BVL:REGN)

Peru flag Peru · Delayed Price · Currency is PEN · Price in USD
736.90
0.00 (0.00%)
At close: Feb 18, 2026
Market Cap272.12B +2.2%
Revenue (ttm)48.25B +1.0%
Net Income15.16B +2.1%
EPS139.55 +8.2%
Shares Outn/a
PE Ratio17.96
Forward PE16.40
Dividend12.61 (1.71%)
Ex-Dividend DateNov 20, 2025
Volumen/a
Average Volumen/a
Openn/a
Previous Close736.90
Day's Rangen/a
52-Week Range564.51 - 750.80
Betan/a
RSI73.21
Earnings DateJan 30, 2026

About Regeneron Pharmaceuticals

Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines to treat various diseases worldwide. The company develops product candidates to treat eye, allergic and inflammatory, cardiovascular, metabolic, neurological, infectious, and rare diseases; and cancer, hematologic conditions. It also offers EYLEA injections for wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; retinopathy of prematurity; Dupixent ... [Read more]

Industry Pharmaceutical Preparations
Founded 1988
Employees 15,410
Stock Exchange Lima Stock Exchange
Ticker Symbol REGN
Full Company Profile

Financial Performance

In 2025, Regeneron Pharmaceuticals's revenue was $14.34 billion, an increase of 0.99% compared to the previous year's $14.20 billion. Earnings were $4.50 billion, an increase of 2.09%.

Financial numbers in USD Financial Statements